JP2005514330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514330A5 JP2005514330A5 JP2003530659A JP2003530659A JP2005514330A5 JP 2005514330 A5 JP2005514330 A5 JP 2005514330A5 JP 2003530659 A JP2003530659 A JP 2003530659A JP 2003530659 A JP2003530659 A JP 2003530659A JP 2005514330 A5 JP2005514330 A5 JP 2005514330A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- butyl
- difluorobenzyl
- optionally substituted
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052736 halogen Inorganic materials 0.000 claims 62
- 150000002367 halogens Chemical class 0.000 claims 62
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 125000004663 dialkyl amino group Chemical group 0.000 claims 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 36
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 206010012289 Dementia Diseases 0.000 claims 22
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 16
- -1 substituted Chemical class 0.000 claims 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 230000003412 degenerative effect Effects 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 6
- BHACQVFKSPPDLM-UHFFFAOYSA-N 3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(N)=O)=C1 BHACQVFKSPPDLM-UHFFFAOYSA-N 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 4
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 241000257303 Hymenoptera Species 0.000 claims 4
- 206010044688 Trisomy 21 Diseases 0.000 claims 4
- 210000004227 basal ganglia Anatomy 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 230000001054 cortical effect Effects 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000004558 lewy body Anatomy 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 claims 1
- IHDYGLQPUPOOQF-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-1,2,4-triazol-5-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC=1NN=CN=1)CC1=CC(F)=CC(F)=C1 IHDYGLQPUPOOQF-UHFFFAOYSA-N 0.000 claims 1
- SFXJLXCQVDVPMQ-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3C=1)C=C2C1=NC=CO1 SFXJLXCQVDVPMQ-UHFFFAOYSA-N 0.000 claims 1
- DCCIFJLXPUVSTK-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CC=1)C=C2C1=NC=CO1 DCCIFJLXPUVSTK-UHFFFAOYSA-N 0.000 claims 1
- WUSLPRMRFGUDMP-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC=1NN=CC=1)CC1=CC(F)=CC(F)=C1 WUSLPRMRFGUDMP-UHFFFAOYSA-N 0.000 claims 1
- CBZUAAHUVIPSKY-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC=CC=1)C=C2C1=NC=CO1 CBZUAAHUVIPSKY-UHFFFAOYSA-N 0.000 claims 1
- PJEOKKZDRSEKFU-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC=1NC=CC=1)CC1=CC(F)=CC(F)=C1 PJEOKKZDRSEKFU-UHFFFAOYSA-N 0.000 claims 1
- WUOSNJNGPXVMCH-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=NC=1)C=C2C1=NC=CO1 WUOSNJNGPXVMCH-UHFFFAOYSA-N 0.000 claims 1
- XQZDLOHEQKVFDU-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC=1NN=NC=1)CC1=CC(F)=CC(F)=C1 XQZDLOHEQKVFDU-UHFFFAOYSA-N 0.000 claims 1
- RPKPQXPESCGNCV-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CC1)C=C2C1=NC=CO1 RPKPQXPESCGNCV-UHFFFAOYSA-N 0.000 claims 1
- WDHCPNAREXWPPA-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC1NC(=O)CC1)CC1=CC(F)=CC(F)=C1 WDHCPNAREXWPPA-UHFFFAOYSA-N 0.000 claims 1
- HZQGLTSJPSXKIC-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CCC1)C=C2C1=NC=CO1 HZQGLTSJPSXKIC-UHFFFAOYSA-N 0.000 claims 1
- BRBMTIKZRMBHLS-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC1NC(=O)CCC1)CC1=CC(F)=CC(F)=C1 BRBMTIKZRMBHLS-UHFFFAOYSA-N 0.000 claims 1
- KIKGANUEXHTONT-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CO)CC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 KIKGANUEXHTONT-UHFFFAOYSA-N 0.000 claims 1
- PCMLQPLBUSSQCO-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(CO)CC1=CC(F)=CC(F)=C1 PCMLQPLBUSSQCO-UHFFFAOYSA-N 0.000 claims 1
- UKFITBRXJWZDIF-UHFFFAOYSA-N 1-butyl-n-[2-(3,5-difluorophenyl)ethyl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NCCC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 UKFITBRXJWZDIF-UHFFFAOYSA-N 0.000 claims 1
- IHXWKLHECBKJEV-UHFFFAOYSA-N 1-butyl-n-[2-(3,5-difluorophenyl)ethyl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NCCC1=CC(F)=CC(F)=C1 IHXWKLHECBKJEV-UHFFFAOYSA-N 0.000 claims 1
- JISSPBPUVKICME-QFIPXVFZSA-N 1-n-[(2s)-1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)N[C@H](CO)CC=2C=C(F)C=C(F)C=2)=C1 JISSPBPUVKICME-QFIPXVFZSA-N 0.000 claims 1
- IRHDCWYPZODAGK-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-1,2,4-triazol-5-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NN=CN=2)=C1 IRHDCWYPZODAGK-UHFFFAOYSA-N 0.000 claims 1
- XUXAJQGPGCMOEK-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NC3=CC=CC=C3C=2)=C1 XUXAJQGPGCMOEK-UHFFFAOYSA-N 0.000 claims 1
- BZKLEGILCVCVRW-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NN=CC=2)=C1 BZKLEGILCVCVRW-UHFFFAOYSA-N 0.000 claims 1
- PXVDKHFQHQUBCI-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NC=CC=2)=C1 PXVDKHFQHQUBCI-UHFFFAOYSA-N 0.000 claims 1
- QJWFUZFAVOWDGV-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NN=NC=2)=C1 QJWFUZFAVOWDGV-UHFFFAOYSA-N 0.000 claims 1
- CZAIKKJMEMJBHM-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC2NC(=O)CC2)=C1 CZAIKKJMEMJBHM-UHFFFAOYSA-N 0.000 claims 1
- FGCRREWITXOSDP-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC2NC(=O)CCC2)=C1 FGCRREWITXOSDP-UHFFFAOYSA-N 0.000 claims 1
- YCMYEVYIGMWBBM-UHFFFAOYSA-N 1-n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NC3=CC=CC=C3N=2)=C1 YCMYEVYIGMWBBM-UHFFFAOYSA-N 0.000 claims 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- NUQGGGIDFQWIFU-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-1,2,4-triazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CN=1)C=C2C1=NC=CO1 NUQGGGIDFQWIFU-UHFFFAOYSA-N 0.000 claims 1
- OVJPUYVERNVDBJ-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-1,2,4-triazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CN=1)C=C2C1=NC=CO1 OVJPUYVERNVDBJ-UHFFFAOYSA-N 0.000 claims 1
- NKYZEWBVEFZKMR-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3C=1)C=C2C1=NC=CO1 NKYZEWBVEFZKMR-UHFFFAOYSA-N 0.000 claims 1
- YMWSLHJVFVZFLE-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3C=1)C=C2C1=NC=CO1 YMWSLHJVFVZFLE-UHFFFAOYSA-N 0.000 claims 1
- NNDNYXNFAVYVMX-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3C=1)C=C2C1=NC=CO1 NNDNYXNFAVYVMX-UHFFFAOYSA-N 0.000 claims 1
- IUKWKSGABPZERY-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CC=1)C=C2C1=NC=CO1 IUKWKSGABPZERY-UHFFFAOYSA-N 0.000 claims 1
- YNHWVRIOWYBQBZ-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CC=1)C=C2C1=NC=CO1 YNHWVRIOWYBQBZ-UHFFFAOYSA-N 0.000 claims 1
- HFXYFEKNOJYCRC-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CC=1)C=C2C1=NC=CO1 HFXYFEKNOJYCRC-UHFFFAOYSA-N 0.000 claims 1
- QKHGYICHUUVYGS-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC=CC=1)C=C2C1=NC=CO1 QKHGYICHUUVYGS-UHFFFAOYSA-N 0.000 claims 1
- YSCCZYIQLYWITG-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC=CC=1)C=C2C1=NC=CO1 YSCCZYIQLYWITG-UHFFFAOYSA-N 0.000 claims 1
- BNQYKUYVKHNHEH-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC=CC=1)C=C2C1=NC=CO1 BNQYKUYVKHNHEH-UHFFFAOYSA-N 0.000 claims 1
- XRUXVYZGNDCMKV-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=NC=1)C=C2C1=NC=CO1 XRUXVYZGNDCMKV-UHFFFAOYSA-N 0.000 claims 1
- LSRXGNNAUBZPAE-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=NC=1)C=C2C1=NC=CO1 LSRXGNNAUBZPAE-UHFFFAOYSA-N 0.000 claims 1
- VTDUFWWEUCKCBF-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=NC=1)C=C2C1=NC=CO1 VTDUFWWEUCKCBF-UHFFFAOYSA-N 0.000 claims 1
- GTMKLWQBKOTLHV-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CC1)C=C2C1=NC=CO1 GTMKLWQBKOTLHV-UHFFFAOYSA-N 0.000 claims 1
- GNJWTCDBLPZBSM-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CC1)C=C2C1=NC=CO1 GNJWTCDBLPZBSM-UHFFFAOYSA-N 0.000 claims 1
- QPEVICIBZKGDFL-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CC1)C=C2C1=NC=CO1 QPEVICIBZKGDFL-UHFFFAOYSA-N 0.000 claims 1
- VGCSKCKTGUNVKO-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CCC1)C=C2C1=NC=CO1 VGCSKCKTGUNVKO-UHFFFAOYSA-N 0.000 claims 1
- JSNGFLHVODTXRS-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CCC1)C=C2C1=NC=CO1 JSNGFLHVODTXRS-UHFFFAOYSA-N 0.000 claims 1
- PRCFBPVZVDCOHK-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CCC1)C=C2C1=NC=CO1 PRCFBPVZVDCOHK-UHFFFAOYSA-N 0.000 claims 1
- WJRBJNQQTFGYSW-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CO)CC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 WJRBJNQQTFGYSW-UHFFFAOYSA-N 0.000 claims 1
- AWKYLEDPGJKVBZ-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CO)CC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 AWKYLEDPGJKVBZ-UHFFFAOYSA-N 0.000 claims 1
- MAFSYLQABRNGGZ-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CO)CC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 MAFSYLQABRNGGZ-UHFFFAOYSA-N 0.000 claims 1
- IRJCDTSTOAETIP-UHFFFAOYSA-N 4-butyl-n-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NCCC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 IRJCDTSTOAETIP-UHFFFAOYSA-N 0.000 claims 1
- IDZQSGYIZVYJHD-UHFFFAOYSA-N 4-butyl-n-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NCCC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 IDZQSGYIZVYJHD-UHFFFAOYSA-N 0.000 claims 1
- FGVMSEHSENMHHK-UHFFFAOYSA-N 4-butyl-n-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NCCC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 FGVMSEHSENMHHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- JEMNNNQAPVQJSZ-UHFFFAOYSA-N n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-1-butyl-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3N=1)C=C2C1=NC=CO1 JEMNNNQAPVQJSZ-UHFFFAOYSA-N 0.000 claims 1
- XDMZDMWZYKEEIR-UHFFFAOYSA-N n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-4-butyl-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3N=1)C=C2C1=NC=CO1 XDMZDMWZYKEEIR-UHFFFAOYSA-N 0.000 claims 1
- UZAOATGNJCHHEW-UHFFFAOYSA-N n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-4-butyl-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3N=1)C=C2C1=NC=CO1 UZAOATGNJCHHEW-UHFFFAOYSA-N 0.000 claims 1
- AQCYABAJBRLJTA-UHFFFAOYSA-N n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-4-butyl-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3N=1)C=C2C1=NC=CO1 AQCYABAJBRLJTA-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 0 C*(C)c1cnn[n]1 Chemical compound C*(C)c1cnn[n]1 0.000 description 2
- YIDCITOHTLPMMZ-UHFFFAOYSA-N CC(C)(C)c1ccn[nH]1 Chemical compound CC(C)(C)c1ccn[nH]1 YIDCITOHTLPMMZ-UHFFFAOYSA-N 0.000 description 1
- XPMMAKUHNMSONL-YFKPBYRVSA-N C[C@@H](CCC1)NC1=O Chemical compound C[C@@H](CCC1)NC1=O XPMMAKUHNMSONL-YFKPBYRVSA-N 0.000 description 1
- PZKFSRWSQOQYNR-UHFFFAOYSA-N Cc1ncn[nH]1 Chemical compound Cc1ncn[nH]1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32440701P | 2001-09-24 | 2001-09-24 | |
| PCT/US2002/030231 WO2003027068A2 (en) | 2001-09-24 | 2002-09-24 | Substituted amines for the treatment of neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514330A JP2005514330A (ja) | 2005-05-19 |
| JP2005514330A5 true JP2005514330A5 (enExample) | 2006-01-05 |
Family
ID=23263441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530659A Pending JP2005514330A (ja) | 2001-09-24 | 2002-09-24 | アルツハイマー病治療のための置換アミン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060100196A1 (enExample) |
| EP (1) | EP1430032A2 (enExample) |
| JP (1) | JP2005514330A (enExample) |
| AU (1) | AU2002356525A1 (enExample) |
| BR (1) | BR0212787A (enExample) |
| CA (1) | CA2461603A1 (enExample) |
| MX (1) | MXPA04002785A (enExample) |
| WO (1) | WO2003027068A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003077847A2 (en) | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Substituted amides |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| HUE028976T2 (en) | 2003-06-17 | 2017-02-28 | Arena Pharm Inc | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| CN1805939B (zh) | 2003-06-17 | 2010-10-13 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关病症的苯并氮杂卓衍生物 |
| TW200524910A (en) * | 2003-08-08 | 2005-08-01 | Schering Corp | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent |
| AU2004311749A1 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease |
| CN1942457A (zh) * | 2004-04-20 | 2007-04-04 | 默克公司 | 作为β－促分泌酶抑制剂用于阿尔茨海默氏病的治疗中的1,3,5－取代的苯基衍生化合物 |
| AU2005257904A1 (en) | 2004-06-15 | 2006-01-05 | Merck Sharp & Dohme Corp. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| JP5270167B2 (ja) | 2004-12-21 | 2013-08-21 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンザゼピン塩酸塩の結晶形 |
| AU2006235344B2 (en) | 2005-04-08 | 2012-07-26 | Comentis, Inc. | Compounds which inhibit beta-secretase activity and methods of use thereof |
| ATE533749T1 (de) * | 2005-05-24 | 2011-12-15 | Vertex Pharma | Modulatoren von atp-bindenden kassettentransportern |
| WO2007120517A2 (en) | 2006-04-03 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
| EP2099743B1 (en) | 2006-12-05 | 2014-08-27 | Arena Pharmaceuticals, Inc. | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
| US8822727B2 (en) | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| CN102648170A (zh) | 2009-06-18 | 2012-08-22 | 艾尼纳制药公司 | 制备5-ht2c受体激动剂的方法 |
| US9045431B2 (en) | 2010-06-02 | 2015-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
| US9365521B2 (en) | 2010-09-01 | 2016-06-14 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-HT2C agonists |
| SG188362A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| EA201390335A1 (ru) | 2010-09-01 | 2013-09-30 | Арена Фармасьютикалз, Инк. | Введение лоркасерина индивидуумам с почечной недостаточностью |
| WO2012030938A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
| WO2014058441A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
| EP2982670B1 (en) * | 2013-04-04 | 2018-11-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9932333B2 (en) | 2014-07-16 | 2018-04-03 | Japan Science And Technology Agency | Benzothiazole compound and medicine containing same |
| EP3364967A2 (en) * | 2015-10-23 | 2018-08-29 | Vifor (International) AG | Ferroportin inhibitors |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| WO2023049953A1 (en) * | 2021-09-30 | 2023-04-06 | TroBio Therapeutics Pty Ltd | Substituted indole compounds and the use thereof |
| CN117229257A (zh) * | 2022-06-06 | 2023-12-15 | 中国药科大学 | 间氨磺酰苯甲酰胺类化合物及制法、药物组合物和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2057145A (en) * | 1934-02-09 | 1936-10-13 | Firm Chem Fab Grunau Landshoff | Pharmaceutical preparation for stimulating the respiratory centre and increasing the circulation |
| US2971027A (en) * | 1956-08-30 | 1961-02-07 | California Research Corp | Diamides of terephthalic acid |
| US4562201A (en) * | 1982-07-26 | 1985-12-31 | American Hospital Supply Corporation | Aminomethyl benzanilides |
| CA1338012C (en) * | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
| US5399565A (en) * | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
| WO1994021621A1 (en) * | 1993-03-23 | 1994-09-29 | Astra Aktiebolag | Guanidine derivatives useful in therapy |
| US5750702A (en) * | 1993-10-27 | 1998-05-12 | Neurogen Corporation | Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands |
| JP3012338B2 (ja) * | 1994-06-29 | 2000-02-21 | ファイザー インク． | アリールおよびヘテロアリールアルコキシナフタレン誘導体 |
| US5741819A (en) * | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| EP1754703A3 (en) * | 1997-02-19 | 2007-02-28 | Berlex, Inc. | N-Heterocyclic derivatives as nos inhibitors |
| CN1158264C (zh) * | 1997-11-21 | 2004-07-21 | Nps药物有限公司 | 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂 |
| GB9800750D0 (en) * | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
| EP1165555B1 (en) * | 1999-03-11 | 2003-07-16 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| CA2376024A1 (en) * | 1999-06-02 | 2000-12-07 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| AU5568400A (en) * | 1999-06-23 | 2001-01-09 | Ajinomoto Co., Inc. | Novel dihydropyrimidine derivatives |
| WO2001021598A1 (en) * | 1999-09-23 | 2001-03-29 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| JP2003527395A (ja) * | 2000-03-17 | 2003-09-16 | ノボ ノルディスク アクティーゼルスカブ | ヒスタミンｈ３受容体リガンドとしての縮環イミダゾール |
| AUPQ969800A0 (en) * | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| WO2002032896A1 (en) * | 2000-10-16 | 2002-04-25 | Novo Nordisk A/S | Furazanyl-triazole derivates for the treatment of diseases |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| WO2002059080A2 (en) * | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| JP2005501073A (ja) * | 2001-08-06 | 2005-01-13 | フアルマシア・イタリア・エツセ・ピー・アー | キナーゼ阻害薬活性を有するアミノイソオキサゾール誘導体 |
| TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| WO2003037900A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazolopyrimidines |
| WO2003045920A1 (en) * | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
-
2002
- 2002-09-24 EP EP02799615A patent/EP1430032A2/en not_active Withdrawn
- 2002-09-24 US US10/490,682 patent/US20060100196A1/en not_active Abandoned
- 2002-09-24 MX MXPA04002785A patent/MXPA04002785A/es not_active Application Discontinuation
- 2002-09-24 WO PCT/US2002/030231 patent/WO2003027068A2/en not_active Ceased
- 2002-09-24 BR BR0212787-3A patent/BR0212787A/pt not_active IP Right Cessation
- 2002-09-24 CA CA002461603A patent/CA2461603A1/en not_active Abandoned
- 2002-09-24 AU AU2002356525A patent/AU2002356525A1/en not_active Abandoned
- 2002-09-24 JP JP2003530659A patent/JP2005514330A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514330A5 (enExample) | ||
| US9096565B2 (en) | Inhibitors of histone deacetylase | |
| US20240132487A1 (en) | Substituted azacyles as trmp8 modulators | |
| ES2977656T3 (es) | Inhibidores de KDM1A para el tratamiento de enfermedades | |
| TWI309165B (en) | Novel morpholine compounds | |
| NO20064151L (no) | Nye forbindelser | |
| TWI648272B (zh) | 經取代之四氫咔唑及咔唑甲醯胺化合物 | |
| YU8703A (sh) | Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1 | |
| SE0104332D0 (sv) | Therapeutic agents | |
| IL107946A (en) | Pyrazoles and pyrazolepyrimidines and pharmaceutical compositions containing them | |
| ATE361287T1 (de) | Neue indol-2-on derivate | |
| JP2005516967A5 (enExample) | ||
| UA79470C2 (en) | Indole, azaindole and related heterocyclic 4-alkenylpiperidine amides | |
| EA011164B1 (ru) | Производные пиримидина для профилактики вич-инфекции | |
| JP2005537303A (ja) | ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法 | |
| YU2803A (sh) | 4-fenil-piridin derivati kao antagonisti neurokinin-1 receptora | |
| CN102971307A (zh) | 作为kv7钾通道开放剂的哌啶基嘧啶酰胺 | |
| CN105579457A (zh) | 取代的n-联苯-3-乙酰基氨基-苯甲酰胺和n-[3-(乙酰基氨基)苯基]-联苯-甲酰胺及其作为wnt信号通路抑制剂用途 | |
| PT1335906E (pt) | Derivados de pirimidina e a sua utilização como ligantes de receptores do neuropéptido y | |
| JP2004525183A5 (enExample) | ||
| TW200902019A (en) | Dicyclic heterocyclic compound | |
| NO20052124L (no) | Nye 1,4-diazabisykloalkanderivater, deres fremstilling og anvendelse | |
| ATE538784T1 (de) | Verfahren zur behandlung von substanzbedingten erkrankungen | |
| UY27034A1 (es) | Derivados de pirimidina | |
| KR970706811A (ko) | I형 알레르기성 질환의 예방 및 치료제(Preventive and remedy for type Ⅰ allergic diseases) |